Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Bone Biologics Corp entered into Purchase Agreement with certain institutional investors valued at 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of (effective 2023-11-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of
- Effective
- 2023-11-16
Exact text from the filing
On November 16, 2023, Bone Biologics Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Direct Offering”), 1,139,063 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of $0.64 per Share.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Bone Biologics Corp entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee (effective 2023-10-30).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee
- Effective
- 2023-10-30
Exact text from the filing
On October 30, 2023, the Company entered into an engagement agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering.
View on SEC.gov